Dramatic response to panitumumab and bevacizumab in metastatic gallbladder carcinoma

Oncologist

Volumn 16, Issue 5, 2011, Pages

  Riley, Elizabeth ^a   Carloss, Harry ^b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b Western Kentucky Hematology and Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PANITUMUMAB;

AGED; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CONTROLLED STUDY; GALLBLADDER CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAPAROTOMY; LETTER; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; WEIGHT REDUCTION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; GALLBLADDER NEOPLASMS; HUMANS; MALE; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 79956289534     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0196     Document Type: Letter

References (2)

1. Phillip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006;24:3069.
2. Ramanathan RK, Belani CP, Singh DA et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial [abstract]. J Clin Oncol 2006;24:180s.